Article
Oncology
Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola J. Lawrence, Robert Motzer, Bradley McGregor, Richard J. Lee, Rohit K. Jain, Nancy Davis, Leonard J. Appleman, Oscar Goodman, Walter M. Stadler, Sunil Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begona Mellado, Juan Manuel Sepulveda Sanchez, Robert Figlin, Thomas Powles, Lalith Akella, Keith Orford, Bernard Escudier
Summary: In this randomized clinical trial, telaglenastat did not improve the efficacy of cabozantinib in metastatic RCC. The progression-free survival and overall response rates between the Tela + Cabo and Pbo + Cabo groups were similar. The rates of treatment-emergent adverse events were also similar between the two groups.
Article
Oncology
Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola J. Lawrence, Robert Motzer, Bradley McGregor, Richard J. Lee, Rohit K. Jain, Nancy Davis, Leonard J. Appleman, Oscar Goodman, Walter M. Stadler, Sunil Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begona Mellado, Juan Manuel Sepulveda Sanchez, Robert Figlin, Thomas Powles, Lalith Akella, Keith Orford, Bernard Escudier
Summary: The study compared the efficacy and safety of telaglenastat plus cabozantinib with placebo plus cabozantinib in patients with advanced renal cell carcinoma. The results showed that telaglenastat did not improve the efficacy of cabozantinib, with no significant differences in progression-free survival and overall response rates between the two groups. The safety profiles were also similar.
Article
Oncology
Stephanie Lheureux, Daniela E. Matei, Panagiotis A. Konstantinopoulos, Ben X. Wang, Ramy Gadalla, Matthew S. Block, Andrea Jewell, Stephanie L. Gaillard, Michael McHale, Carolyn McCourt, Sarah Temkin, Eugenia Girda, Floor J. Backes, Theresa L. Werner, Linda Duska, Siobhan Kehoe, Ilaria Colombo, Lisa Wang, Xuan Li, Rachel Wildman, Shirin Soleimani, Scott Lien, John Wright, Trevor Pugh, Pamela S. Ohashi, David G. Brooks, Gini F. Fleming
Summary: This study explored the combination of immunotherapy and antiangiogenic agents in the treatment of endometrial cancer. Adding cabozantinib to nivolumab significantly improved outcomes in heavily pretreated endometrial cancer patients. The identification of immunotherapy-pretreated patients based on baseline immune profiling can help determine who might benefit from combination treatment with antiangiogenics.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Christina A. Wicker, Brian G. Hunt, Sunil Krishnan, Kathryn Aziz, Shobha Parajuli, Sarah Palackdharry, William R. Elaban, Trisha M. Wise-Draper, Gordon B. Mills, Susan E. Waltz, Vinita Takiar
Summary: The study demonstrates that the glutaminase inhibitor, telaglenastat, enhances the sensitivity of head and neck cancer cells to ionizing radiation, leading to an enhanced anti-tumor response.
Article
Oncology
Taihang Shao, Mingye Zhao, Wenxi Tang
Summary: Sintilimab plus chemotherapy is likely to be a cost-effective option for the treatment of advanced OSCC, providing additional benefits in terms of quality-adjusted life-years and life-years gained.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Sumanta K. Pal, Bradley McGregor, Cristina Suarez, Che-Kai Tsao, William Kelly, Ulka Vaishampayan, Lance Pagliaro, Benjamin L. Maughan, Yohann Loriot, Daniel Castellano, Sandy Srinivas, Rana R. McKay, Robert Dreicer, Thomas Hutson, Sarita Dubey, Scott Werneke, Ashok Panneerselvam, Dominic Curran, Christian Scheffold, Toni K. Choueiri, Neeraj Agarwal
Summary: The study showed that the combination of cabozantinib plus atezolizumab has promising clinical activity and acceptable tolerability in patients with advanced ccRCC and nccRCC. Disease control was observed across dose levels and histologic subtypes.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Wei Li, Li Wan
Summary: This study aimed to evaluate the cost-effectiveness of sugemalimab plus chemotherapy compared to placebo plus chemotherapy as first-line treatment for non-small cell lung cancer in China. The results showed that from the perspective of the Chinese healthcare system, sugemalimab plus chemotherapy was not cost-effective compared to placebo plus chemotherapy.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Oncology
Chester Kao, Daniel J. George, Tian Zhang
Summary: The case demonstrates the potential of combination cabozantinib plus nivolumab therapy in salvaging disease control in refractory metastatic renal cell carcinoma, and highlights the potential efficacy of vascular endothelial growth factor inhibitors and immune checkpoint inhibitors combination therapy.
Article
Oncology
Romualdo Barroso-Sousa, Tanya E. Keenan, Tianyu Li, Nabihah Tayob, Lorenzo Trippa, Ricardo G. Pastorello, Edward T. Richardson, Deborah Dillon, Zohreh Amoozgar, Beth Overmoyer, Stuart J. Schnitt, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer Van Allen, Dan G. Duda, Sara M. Tolaney
Summary: This single-arm phase II study evaluating the combination of cabozantinib and nivolumab in metastatic triple-negative breast cancer did not show significant efficacy, and was stopped early due to toxicity. High levels of tumor immunosuppression were observed, as indicated by immunostaining, genomic, and proteomic studies.
Article
Oncology
Yansong Lin, Shukui Qin, Zhiyong Li, Hui Yang, Wei Fu, Shaohua Li, Wenxin Chen, Zairong Gao, Weibing Miao, Huiqin Xu, Qing Zhang, Xinming Zhao, Jiandong Bao, Linfa Li, Yuan Ren, Chenghe Lin, Shanghua Jing, Qingjie Ma, Jun Liang, Guang Chen, Hong Zhang, Yifan Zhang, Xianfeng Zhou, Yaxiong Sang, Zhiguo Hou
Summary: The study aimed to assess the efficacy and safety of apatinib in patients with progressive locally advanced or metastatic RAIR-DTC. Results showed that apatinib demonstrated significant clinical benefits in terms of prolonged PFS and improved overall survival with manageable safety profile.
Article
Biochemistry & Molecular Biology
Koji Iinuma, Risa Tomioka-Inagawa, Koji Kameyama, Tomoki Taniguchi, Kei Kawada, Takashi Ishida, Shingo Nagai, Torai Enomoto, Shota Ueda, Makoto Kawase, Shinichi Takeuchi, Kota Kawase, Daiki Kato, Manabu Takai, Keita Nakane, Takuya Koie
Summary: A multicenter retrospective study evaluated the efficacy and safety of cabozantinib in patients with advanced or metastatic renal cell carcinoma. The study found that cabozantinib is a useful treatment option for mRCC patients and may benefit from earlier use. Additionally, high CRP levels may be a poor prognostic factor in patients treated with cabozantinib, requiring careful follow-up.
Article
Oncology
Jonathan W. Riess, Paul Frankel, David Shackelford, Mark Dunphy, Ramsey D. Badawi, Lorenzo Nardo, Simon R. Cherry, Ian Lanza, Joel Reid, Wilson Gonsalves, Charles Kunos, David R. Gandara, Primo N. Lara, Edward Newman, Paul K. Paik
Summary: This study aims to evaluate the safety and preliminary efficacy of the combination therapy of MLN0128 and CB-839 in lung cancer, with a focus on subsets of LSCC and KRAS-mutant LUAD patients harboring NFE2L2 or KEAP1 mutations.
CLINICAL LUNG CANCER
(2021)
Article
Oncology
Haoran Li, Kamal Kant Sahu, James Brundage, Mallory Benson, Umang Swami, Kenneth M. Boucher, Sumati Gupta, Josiah Hawks, Deepika Sirohi, Neeraj Agarwal, Benjamin L. Maughan
Summary: This phase I trial evaluated the safety and clinical activity of combined therapy with avelumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma. The results demonstrated that this combination therapy is safe and showed positive clinical responses in some patients.
Article
Oncology
Michael H. Storandt, Jennifer J. Gile, Mathias E. Palmer, Tyler J. Zemla, Daniel H. Ahn, Tanios S. Bekaii-Saab, Zhaohui Jin, Nguyen H. Tran, Amit Mahipal
Summary: This study retrospectively analyzed the clinical outcomes of patients with advanced hepatocellular carcinoma who received cabozantinib after progression on immunotherapy. The study found that patients may benefit from treatment with cabozantinib following progression on immunotherapy, and most patients had a manageable side effect profile.
Article
Oncology
Funda Meric-Bernstam, Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan, Angela DeMichele, Naomi B. Haas, Manish R. Patel, James J. Harding, Martin H. Voss, Taofeek K. Owonikoko, Bradley Carthon, Ramaprasad Srinivasan, Johanna C. Bendell, Yonchu Jenkins, Sam H. Whiting, Keith Orford, Mark K. Bennett, Todd M. Bauer
Summary: TelaE and TelaC showed promising clinical activity and tolerability in heavily pretreated metastatic renal cell carcinoma patients.
CLINICAL CANCER RESEARCH
(2022)
